Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 2712345...1020...Last »

Allergan, Molecular Partners eye drug abicipar meets main goal in two studies

Allergan and Molecular Partners’ drug for neovascular age-related macular degeneration met the main goal in two late-stage studies.

Read More »

Pfizer-Lilly pain drug meets late-stage trial goals

An experimental osteoarthritis drug developed by Pfizer Inc. and Eli Lilly and Co. achieved its main goal of lowering pain in a late-stage clinical trial.

Read More »

Roche touts new flu drug

Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.

Read More »

Zogenix’s seizure drug clears late-stage trial

Zogenix Inc.’s drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer’s shares up as much as 26 percent.

Read More »

AbbVie Stock Drops After Disappointing Clinical Trial Update

AbbVie’s shares dropped after releasing an update on the company’s Phase III B-cell lymphoma trial.

Read More »

Israeli firm gets U.S. nod for advanced trials for non-opiate painkiller

PainReform received FDA clearance to begin late-stage studies for a pain-relief drug that is a departure from opiate-based narcotics.

Read More »

Celgene and Acceleron’s Luspatercept Hits Primary Endpoints in Beta-Thalassemia Trial

Celgene Corporation and Acceleron Pharma Inc. indicated the companies’ Phase III clinical trial of luspatercept in beta-thalassemia hit its primary endpoint of erythroid response.

Read More »

CTI BioPharma’s cancer drug fails late-stage trial, shares tumble

CTI BioPharma Corp.’s treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending the company’s shares down 17 percent.

Read More »

Lilly’s Taltz Hits Endpoints in AS Study

Eli Lilly announced the results of the company’s COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat ankylosing spondylitis. The study met both primary and major secondary endpoints.

Read More »

GBT’s sickle cell disease drug meets trial goal

Global Blood Therapeutics’ sickle cell disease treatment met the main goal of a late-stage trial, but there is scepticism over whether the drug would get an accelerated review from health regulators.

Read More »

Summit’s muscle-wasting disorder drug fails study

Britain’s Summit Therapeutics will stop developing the company’s Duchenne muscular dystrophy drug after ezutromid failed a mid-stage study, wiping out nearly 80 percent of its market value.

Read More »

Aquinox to stop development of lead drug

Aquinox Pharmaceuticals Inc. plans to stop developing its main drug to treat bladder pain syndrome as rosiptor failed to meet the main goal of a late-stage trial, pushing the company’s shares down as much as 85 percent.

Read More »

AstraZeneca, Merck eye $1 billion boost from cancer drug success

AstraZeneca’s oncology business received a boost as results of a clinical trial showed the company’s drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

Read More »

Breast cancer drug combo falls short of survival goal

A combination of Pfizer’s breast cancer medicine Ibrance and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial.

Read More »

Lilly’s Jardiance meets main goal of two diabetes trials

Eli Lilly and Co.’s Jardiance, along with insulin therapy, met the main goal of two trials testing the company’s drug in patients with type 1 diabetes.

Read More »

Merrimack to scrap development of pancreatic cancer treatment

Merrimack Pharmaceuticals Inc. will stop developing the company’s experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.

Read More »

Study preserves hopes for Roche’s Tecentriq in lung cancer

A clinical trial showed positive survival data for Swiss drugmaker Roche’s potential immunotherapy cocktail as an initial treatment for an aggressive form of lung cancer.

Read More »

Trends and Challenges in Fibromyalgia Drug Research

Growth in fibromyalgia drug research over the past five years has made site selection a far less taxing prospect. There are now hundreds of sites capable of performing this research, and the challenge is to gather current feedback on them.

Read More »

UroGen to start mid-stage bladder cancer trial

UroGen Pharma plans to begin a mid-stage trial of the company’s treatment for bladder cancer patients after positive interim results from an advanced trial of a treatment for upper urinary tract cancer.

Read More »

Sarepta gene therapy study shows promise

Sarepta Therapeutics shares jumped 60 percent after reporting promising results from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD).

Read More »

Page 1 of 2712345...1020...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2018 Focus: Biotech, Payer Access, DTC and more!


Ad Right Bottom

Main Navigation